MINNEAPOLIS--(BUSINESS WIRE)--April 25, 2006--Based in part on promising study results presented this week at an international neurosurgical meeting, Medtronic, Inc. (NYSE:MDT - News), today announced its intentions to pursue a major clinical trial of the company’s deep brain stimulation (DBS) technology in the treatment of severe and intractable depression, a disabling form of the psychiatric disorder affecting millions of people worldwide.
